7 results match your criteria: "Campus Kiel and Christian Albrechts-University of Kiel[Affiliation]"

Adaptive Deep Brain Stimulation in Parkinson's Disease: A Delphi Consensus Study.

medRxiv

August 2024

"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via Antonio di Rudinì 8, 20142 Milan, Italy.

Article Synopsis
  • The evolution of Deep Brain Stimulation (DBS) is shifting from conventional methods to adaptive techniques (aDBS), which are expected to become standard practice in the next decade, similar to past advancements in cardiac pacing.
  • Research involving 21 experts highlighted the challenges and potential of aDBS, showing consensus on its safety and effectiveness compared to conventional DBS, particularly for Parkinson's Disease patients with motor fluctuations and dyskinesias.
  • Further studies are necessary to refine the algorithms used in aDBS, ensuring its widespread and effective use in clinical settings.
View Article and Find Full Text PDF

Background: Head tremor is common in dystonia syndromes and difficult to treat. Deep brain stimulation (DBS) is a therapeutic option in medically-refractory cases. In most DBS-centers, the globus pallidus internus (GPi) is targeted in patients with predominant dystonia and the ventrointermediate nucleus of the thalamus (Vim) in predominant tremor.

View Article and Find Full Text PDF

Background: Thalamic deep brain stimulation (DBS) is established for medically refractory tremor syndromes and globus pallidus stimulation (GPi-DBS) for medically refractory dystonia syndromes. For combined tremor and dystonia syndromes, the best target is unclear.

Objectives: We present four patients with two different profiles whose clinical course demonstrates that our current analysis of clinical symptomatology is not a sufficient predictor of surgical success.

View Article and Find Full Text PDF

Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica.

Clin Exp Rheumatol

July 2017

Department of Rheumatology and Immunology, Klinikum Bad Bramstedt, Bad Bramstedt; and Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany.

Objectives: To date, no specific serum marker for giant cell arteritis and polymyalgia rheumatica has been established in routine practice. Therefore, the aim of this study was to examine whether immunoglobulin G4 serum concentrations could be a potential biomarker for the differentiation of both diseases.

Methods: Serum immunoglobulin G4 (IgG4) concentrations were measured in patients with giant cell arteritis (n=41) and polymyalgia rheumatica (n=27) by an in-house enzyme-linked immunosorbent assay.

View Article and Find Full Text PDF

Objective: To compare the phenotype, clinical course, and outcome of myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) (GPA) to proteinase 3 (PR3)-ANCA-positive GPA and to MPO-ANCA-positive microscopic polyangiitis (MPA).

Methods: We characterized all MPO-ANCA-positive patients classified as having GPA by the European Medicines Agency algorithm who attended our center, in a retrospective chart review. A second cohort of patients with PR3-ANCA-positive GPA matched for age and sex was characterized.

View Article and Find Full Text PDF